Inactive Instrument

Other languages Sensidose AB

Equities

SENSI

SE0017232671

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

Updated recommendation by the nomination committee of Navamedic ASA	23-05-31
Navamedic announces the final outcome in the offer to the shareholders and holders of warrants of series TO 1 in Sensidose Aktiebolag	23-05-26
Navamedic to own a total of 96.33 per cent of shares in Sensidose following closing of public offer	23-05-26
Navamedic ASA (OB:NAVA) completed the acquisition of Sensidose AB.	23-05-24
EQL Pharma AB publishes the final outcome in public takeover offer. As a result of the shareholder dynamics and other circumstances the Board also announces its intention to sell its holdings.	23-05-17
EQL Pharma AB cancelled the acquisition of all the remaining stake in Sensidose AB.	23-05-16
Navamedic ASA Q1 2023: Another strong quarter	23-05-11
Navamedic increases the consideration to SEK 8.50 in cash per share in its unconditional public offer and convenes an extraordinary general meeting of Sensidose Aktiebolag	23-05-10
Sensidose AB Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-05
Navamedic publishes a supplement to the offer document regarding the unconditional cash offer to the shareholders and holders of warrants of series TO 1 in Sensidose Aktiebolag	23-04-28
Navamedic increases the consideration to SEK 0.60 in cash per warrant of series TO 1 in its unconditional offer to the warrant holders in Sensidose Aktiebolag	23-04-26
EQL Pharma extends the unconditional offer to include warrants series TO 1 and publishes a supplementary offer document regarding EQL Pharma's offer to the shareholders of Sensidose	23-04-26
Navamedic ASA expands its offer to include warrants of series TO 1 issued by Sensidose Aktiebolag at a price of SEK 0.38 in cash per warrant of series TO 1	23-04-25
Correction: Navamedic publishes a supplement to the offer document regarding the cash offer to the shareholders of Sensidose Aktiebolag	23-04-24
Navamedic publishes a supplement to the offer document regarding the recommended cash offer to the shareholders of Sensidose Aktiebolag	23-04-24
Offer document regarding EQL Pharma's offer to the shareholders of Sensidose Aktiebolag published	23-04-24
Sweden’s EQL Pharma Increases Bid for Sensidose	23-04-24
EQL Pharma AB announces a revised unconditioned cash offer of SEK 8.40 per share to the shareholders of Sensidose Aktiebolag	23-04-24
Navamedic Raises Takeover Offer for Sensidose, Agrees to Buy 57% Stake	23-04-24
Navamedic ASA: Amended cash offer to acquire Sensidose AB and acquisition of shares in Sensidose AB	23-04-22

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Sensidose AB

Equities

SENSI

SE0017232671

Other languages

Filters